Skip to content
2000
Volume 5, Issue 10
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The discovery and development of selective, efficacious, and safe small molecule p38 mitogen-activated protein kinase inhibitors for the treatment of inflammatory diseases remains the focus of many pharmaceutical research programs. Advances in small molecule p38 inhibitor design in potency and oral efficacy have been accelerated with the large number of available inhibitor-enzyme x-ray structures. These advances have allowed for the discovery of diverse sets of inhibitors with the opportunity to map inhibitor interactions and design selective inhibitors. This review covers recent compound disclosures in the patent and published literature over the last three years. Many disclosures represent new chemotypes as well as creative modifications of known structures.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026054985920
2005-09-01
2025-05-23
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026054985920
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test